|Title||Multimodality tumor control and living donor transplantation for unresectable hepatocellular carcinoma|
|Publication Type||Journal Article|
|Year of Publication||2004|
|Authors||Chui AK, Rao AR, Island ER, Chan HL, Leung TW, Lau WY|
|Pagination||2287 - 8|
|Keywords||*Living Donors, Cadaver, Carcinoma, Hepatocellular / pathology / *surgery, Female, Humans, Liver Neoplasms / pathology / *surgery, Liver Transplantation / *methods / mortality / *physiology, Male, Neoplasm Staging, Retrospective Studies, Survival Analysis, Time Factors, Tissue Donors, Treatment Outcome, Waiting Lists|
Liver transplantation (LT) is an acceptable mode of treatment for selected patients with unresectable hepatocellular carcinoma (HCC). However, due to the scarcity of cadaveric donor organs, it is considered desirable for patients to opt for living donor liver transplantation (LDLT) or, for those not being transplanted soon, to have some form of tumor control therapy. Such an approach in our program is analyzed and reported. At our institution, 42 LTs were performed between October 1999 and April 2003. Of these, 18 recipients (15 men, 3 women) had 27 HCC. The average number and size of HCC was 1.59 (1 to 4) and 2.31 (0.2 to 6.5) cm, respectively. Thirteen (72%) patients were transplanted primarily for the HCC, whereas five (28%) others were incidental HCC cases. Seven patients (5 LRLT, 2 cadaveric LT) were transplanted soon after listing, and thus did not require tumor control therapy. Six patients waited for 11 (6 to 19) months before LT. Three patients underwent microwave coagulation therapy, and one had additional alcohol injections. One patient received the novel PIAF (cisplatin, interferon, adriamycin, and 5-FU) chemotherapy regimen followed by selective internal irradiation (SIR) treatment. One patient received conformal radiation therapy and another received SIR treatment before LT. Besides 2 postoperative deaths, the remaining 16 patients have been well, with a mean follow-up of 20.4 (3.6 to 41.2) months. In conclusion, for patients with unresectable HCC, in areas with poor cadaveric donor rate, living donation should be the first option. If a suitable live donor is not available, aggressive multimodality therapy is recommended while waiting for cadaveric LT.
|Notify Library Reference ID||345|